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Abstract
Background: The Global Burden of Disease 2000 (GBD 2000) study starts from an analysis of the
overall mortality envelope in order to ensure that the cause-specific estimates add to the total all
cause mortality by age and sex. For regions where information on the distribution of cancer deaths
is not available, a site-specific survival model was developed to estimate the distribution of cancer
deaths by site.
Methods: An age-period-cohort model of cancer survival was developed based on data from the
Surveillance, Epidemiology, and End Results (SEER). The model was further adjusted for the level
of economic development in each region. Combined with the available incidence data, cancer death
distributions were estimated and the model estimates were validated against vital registration data
from regions other than the United States.
Results: Comparison with cancer mortality distribution from vital registration confirmed the
validity of this approach. The model also yielded the cancer mortality distribution which is
consistent with the estimates based on regional cancer registries. There was a significant variation
in relative interval survival across regions, in particular for cancers of bladder, breast, melanoma of
the skin, prostate and haematological malignancies. Moderate variations were observed among
cancers of colon, rectum, and uterus. Cancers with very poor prognosis such as liver, lung, and
pancreas cancers showed very small variations across the regions.
Conclusions: The survival model presented here offers a new approach to the calculation of the
distribution of deaths for areas where mortality data are either scarce or unavailable.
Background
As a part of the Global Burden of Disease 2000 (GBD
2000) project, the present study aims at estimating the to-
tal global and regional cancer mortality and incidence
based on its detailed analysis of all-cause levels and cause
of death distributions for 191 Member States of the World
Health Organization (WHO) [1]. GBD 2000 requires age-
and sex- specific incidence, duration and mortality as a
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minimum input to estimate burden of each disease seque-
la by a composite measure of mortality and morbidity
(i.e., disability-adjusted life years: DALYs).
Attempts have been made to quantify the global burden
of cancer, and estimate site-specific cancer mortality and
morbidity [2–6]. Such studies have repeatedly suggested
that incidence and mortality from cancer are continuously
increasing in many parts of the world. Despite an increas-
ing trend of cancer incidence and mortality, data on sur-
vival and prognosis of incident cases from population-
based cancer registries are limited in majority of develop-
ing countries. One of the most credible sources of infor-
mation is available from the International Agency for
Research on Cancer (IARC), which has been coordinating
and implementing the cancer registries in such regions
[7].
While vital registration of causes of death and national
cancer registries are perhaps the best source of data on
cancer mortality, mortality data are still scarce, poor or
even unavailable for some regions of the world. Innova-
tive methods will thus continue to be needed to exploit
available data. Estimating mortality from morbidity and,
especially, morbidity from mortality was a common prac-
tice in the 70's and 80's [8,9]. More recently, the continu-
os effort made by IARC has lead to the Globocan 2000
estimates which has also used information on incidence
and survival to estimate cancer death for the year 2000
from various sources including cancer registries [2,6]. Still
others have made use of vital statistics and cancer inci-
dence data to predict the number of new cancer cases and
deaths for the US in the subsequent year [10].
On the basis of available published information on age-,
sex-, and site-specific cancer incidence and survival, we de-
veloped an algorithm to estimate region-specific overall
cancer mortality, and site-specific survival, death distribu-
tions and incidence for the year 2000. This paper presents
the first of the two consecutive reports which present the
detailed methods and results of GBD 2000 estimates for
mortality and incidence of cancer by site.
The particular feature of the GBD 2000 study is that the
number of deaths by age and sex in each region provides
an essential envelope which constrains individual disease
and injury estimates of deaths and that competing claims
for the magnitude of deaths from various causes must be
reconciled within this envelope [1]. Given the regional
cancer mortality envelope by age and sex, the estimates of
site-specific distributions of cancer mortality are necessary
to disagreggate the estimated total cancer deaths by age
and sex for each region.
For geographic disaggregation of the GBD 2000, the six
WHO regions of the world have been further divided into
14 sub regions, based on levels of child (under five years)
and adult (15–59 years) mortality for WHO Member
States [1]. Five mortality strata were defined in terms of
quintiles of the distribution of child and adult mortality
(both sexes combined). Adult mortality was regressed on
child mortality and the regression line used to divide
countries with high child mortality into high adult mor-
tality (stratum D) and very high adult mortality (stratum
E). Stratum E includes the countries in sub-Saharan Africa
where HIV/AIDS has had a very substantial impact.
When these mortality strata are applied to the six WHO re-
gions, they produce 14 mortality subregions. For the pur-
poses of burden of disease epidemiological analyses, 2 of
these regions were further subdivided: EurB into EurB1
and EurB2 – the latter including the central Asian states;
and WprB into WprB1 (mainly China), WprB2 (South
East Asian countries) and WprB3 (Pacific Islands). Addi-
tionally, some Member States have been reclassified into
subregions with similar epidemiological/geographic/eth-
nic patterns in order to maximise the epidemiological ho-
mogeneity of the subregions for the purposes of
epidemiological analysis. The resulting 17 epidemiologi-
cal subregions are listed in Table 1.
The approaches to estimating mortality distributions were
different depending on the availability and quality of data
on detailed causes of death. Direct estimates of the site-
specific distributions of cancer mortality were possible for
the regions where established vital registration records
with high coverage and coding practice based on the Inter-
national Statistical Classification of Diseases and Related
Health Problems (ICD) are available, including countries
in the A sub regions (AmrA, EurA and WprA) and coun-
tries in AmrB, EurB1, EurB2 and EurC [1]. For the other re-
gions of the world (AfrD, AfrE, AmrD, EmrB, EmrD,
SearB, SearD, WprB1, WprB2 and WprB3), we developed
a site-specific model for relative interval survival adjusted
for each region and applied it to the regional incidence es-
timated to calculate the mortality distribution by site for
the year 2000. This model can also be used to estimate
survival at different ages and average duration of cancer by
site. In this paper, we present a detailed model as a key in-
put to estimate the distribution of cancer deaths by site
model for the regions where few data are available.
Material and Methods
Data sources
Relative interval survival based on the US data
The primary data sources used to develop the cancer sur-
vival model were the National Cancer Institute Surveil-
lance, Epidemiology, and End Results (SEER) statistical
program (SEER*Stat version 4.2). The SEER program isBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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considered as the standard for quality among cancer regis-
tries around the world, being the most authoritative
source of information on cancer incidence and survival in
the United States [11], RIS was directly obtained from the
SEER database (1973–1997 Public-Use Data) within SE-
ER*Stat for every age group, sex, and cancer site. Cancer
sites for which survival was calculated were: mouth and
pharynx (ICD-10 C00-C14), oesophagus (C15), stomach
(C16), colon and rectum (C18-C21), liver (C22), pancre-
as (C25), trachea, bronchus and lung (C33-C34), melano-
ma of the skin (C43), female breast (C50), cervix uteri
(C53), corpus uteri (C54-55), ovary (C56), prostate
(C61), bladder (C67), lymphomas and multiple myelo-
ma (C81-C90, C96), leukaemia (C91-C95), and other
malignant neoplasms (balance of ICD-10 C00-C97).
Incidence data
We initially used the Globocan 2000 estimates of the in-
ternational Agency for Research on Cancer (IARC) to ap-
ply the survival model for a region [6], assuming that
incidence rates to be constant over the years. We then es-
timated the region-specific number of new cases for 1986
to 2000, by applying these age-specific incidence rates to
the annual population. We carefully examined the meth-
ods used to estimate country-specific incidence data in
Globocan 2000, to ensure that for all the regions where
we required incidence estimates, the Globocan estimates
were based on cancer registry incidence data, and not
modelled from mortality data using assumptions about
survival (which would then result in circularity in our
mortality estimation process for regions without good
mortality data by cancer site).
Table 1: Global Burden of Disease 2000 (GBD 2000) project: regions and sub regions
WHO region Mortality stratum Sub region WHO Member States
AFRO D AfrD Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Comoros, 
Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, 
Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome And Princ-
ipe, Senegal, Seychelles, Sierra Leone, Togo, Djibouti, Somalia, Sudan
AFRO E AfrE Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Demo-
cratic Republic Of The Congo, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, 
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United 
Republic of Tanzania, Zambia, Zimbabwe
AMRO A AmrA Canada, United States Of America
AMRO B AmrB Antigua And Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, 
Colombia, Costa Rica, Dominica, Dominican Republic, El Salvador, Grenada, 
Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts And Nevis, 
Saint Lucia, Saint Vincent And The Grenadines, Suriname, Trinidad And 
Tobago, Uruguay, Venezuela
Cuba
AMRO D AmrD Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru
EMRO B EmrB Bahrain, Cyprus, Iran (Islamic Republic Of), Jordan, Kuwait, Lebanon, Libyan 
Arab Jamahiriya, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, 
United Arab Emirates
EMRO D EmrD Egypt, Iraq, Morocco, Yemen
EURO A EurA Andorra, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, 
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, 
Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzer-
land, United Kingdom
EURO B1 EurB1 Albania, Bosnia And Herzegovina, Bulgaria, Georgia, Poland, Romania, Slovakia, 
The Former Yugoslav Republic Of Macedonia, Turkey, Yugoslavia
EURO B2 EurB2 Armenia, Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan
EURO C EurC Republic of Moldova, Russian Federation, Ukraine
SEARO B SearB Indonesia, Sri Lanka, Thailand Malaysia, Philippines Brunei Darussalam, Singa-
pore
SEARO D SearD Bangladesh, Bhutan, India, Maldives, Nepal Afghanistan, Pakistan
WPRO A WprA Australia, Japan, New Zealand
WPRO B1 WprB1 China, Mongolia, Republic Of Korea DPR Korea
WPRO B2 WprB2 Cambodia, Lao People's Democratic Republic, Viet Nam Myanmar
WPRO B3 WprB3 Cook Islands, Fiji, Kiribati, Marshall Islands, Micronesia (Federated States Of), 
Nauru, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tonga, 
Tuvalu, VanuatuBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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Globocan 2000 estimates of cancer incidence by site for
countries differ from those required for the GBD 2000 in
two major respects: 1) Globocan 2000 estimates include
Kaposi's sarcoma and non-Hodgkin lymphomas (NHL)
caused by HIV/AIDS. The GBD 2000 includes these cases
among AIDS sequela and their burden is included with
the HIV/AIDS burden [12–14] and 2) Globocan 2000 es-
timates include cancers of unknown primary with cancers
of other specified sites. The GBD 2000 attributes these ill-
defined cancers back to specific sites as described above.
Accordingly Globocan 2000 incidence estimates by age,
sex, site and country were adjusted for these differences.
Firstly, unpublished data on the incidence of Kaposi's sar-
coma for countries in Africa were provided by IARC and
used to adjust incidence of other cancers to remove inci-
dence of Kaposi's sarcoma. Secondly, relative risks of HNL
from HIV [15–18] were estimated and, together with the
UNAIDS prevalence estimates of HIV in each country of
the African region, NHL attributable to HIV was also re-
moved. Thirdly, incidence estimates for cancers of un-
known primary site were redistributed among specific
sites using the GBD 2000 algorithm [1]. The proportion of
the others category (balance of all but skin cancers) in the
Globocan 2000 corresponding to unknown primary sites
was estimated from published data on the distribution of
cancer incidence by site which included unknown prima-
ry as a specific category [19–27].
After adjusting the Globocan 2000 incidence estimates for
each country as described above, these estimates were
summed for the countries in each GBD 2000 region, re-
sulting in estimated incidence distributions by site, age
and sex for each region. Finally, the GBD 2000 uses the
latest population estimates for the Member States of the
World Health Organization prepared by the United Na-
tions Population Division [28]. In order to obtain inci-
dence from 1986 to 2000, we estimated the age-specific
population by sex for each of these years, using growth
rates also from the United Nation's data.
Multiplicative model of relative interval survival
In order to estimate cancer death distribution for regions
where little cancer mortality data is available (AfrD, AfrE,
AmrD, EmrB, EmrD, SearB, SearD, WprB1, WprB2 and
WprB3 sub regions), we developed an age-period-cohort
multiplicative model for the relative interval survival
(RIS) for each site. To incorporate all three time dimen-
sions, we have taken into account the relative survival for
every 5-year age group from 0 up to 85+ years of age, and
for calendar year for 15 years (1981 to 1995), and for time
since cancer diagnosis (survival time for cohorts) from 1-
up to 15-year survival. After obtaining the time-specific
survival data, we have then further indexed all the age,
time, and calendar year survival information to the first
year interval survival for each sex, and cancer site. The first
year of survival was chosen because, for most if not all
cancer sites, it is the most critical year concerning cancer
survival experience. After the first year of survival, the rel-
ative survival curve usually increases and then flattens
smoothly. Indexing was done by dividing each of the
time-specific RIS by the survival at 1-year interval.
Table 2: Estimated relative probability of death after 1 year (1 - RIS1)
Site Males Females
Mouth and pharynx 0.202 0.180
Oesophagus 0.660 0.635
Stomach 0.574 0.558
Colon and rectum 0.207 0.223
Trachea, bronchus and lung 0.831 0.769
Pancreas 0.828 0.816
Lung 0.631 0.568
Melanoma of the skin 0.052 0.029
Breast 0.039
Cervix 0.126
Uterus 0.073
Ovary 0.289
Prostate 0.037
Bladder 0.091 0.153
Non-Hodgkin lymphoma 0.297 0.253
Hodgkin lymphoma 0.108 0.089
Multiple myeloma 0.286 0.297
Leukemia 0.360 0.376
Others 0.348 0.386BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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Table 3: Estimated age parameters (Aα) by cancer site, age and sex
Oral Oesophagus Stomach Colon and rectum Liver Pancreas
Age Male Female Male Female Male Female Male Female Male Female Male Female
0–4 0.870 1.093 0.957 0.944 0.864 0.814 1.169 0.288 0.330 0.388 0.824 0.408
5–9 0.429 0.222 0.957 0.944 0.864 0.814 1.169 0.288 0.430 0.600 0.824 0.408
10–14 0.216 0.258 0.957 0.944 0.864 0.814 1.169 0.288 0.527 0.315 0.824 0.613
15–19 0.185 0.200 0.957 0.944 0.864 0.814 1.169 0.688 0.225 0.585 0.824 0.204
20–24 0.337 0.099 0.957 0.944 0.864 0.895 1.169 0.467 0.580 0.638 0.824 0.204
25–29 0.710 0.177 0.957 0.944 0.864 0.888 1.169 0.820 0.818 0.689 0.824 0.531
30–34 0.913 0.314 0.957 0.944 0.864 0.685 1.169 0.590 0.949 0.773 0.824 0.497
35–39 0.761 0.436 0.957 0.888 0.864 0.811 0.966 0.700 0.960 0.752 0.893 0.712
40–44 0.818 0.526 0.957 0.985 0.864 0.746 0.765 0.739 1.033 0.780 0.907 0.745
45–49 0.883 0.631 0.965 0.977 0.931 0.791 0.787 0.687 0.974 0.819 0.927 0.902
50–54 0.908 0.894 0.969 1.036 0.899 0.851 0.784 0.671 0.980 0.969 0.936 0.922
55–59 0.936 0.939 0.948 0.996 0.877 0.816 0.797 0.739 1.010 0.962 0.977 0.952
60–64 1.017 0.884 0.967 0.959 0.940 0.863 0.812 0.749 1.023 0.998 0.986 0.970
65–69 1.048 1.086 1.029 0.949 0.972 0.923 0.861 0.857 1.010 1.025 1.015 0.989
70–74 1.145 1.103 1.038 0.975 0.990 0.982 0.979 0.898 1.051 1.034 1.016 1.020
75–79 1.141 1.304 1.063 0.969 1.082 1.055 1.134 1.069 1.032 1.082 1.016 1.033
80–84 1.220 1.354 1.096 1.066 1.169 1.121 1.368 1.275 1.070 1.126 1.061 1.058
85+ 1.358 1.993 1.152 1.210 1.259 1.279 1.793 1.619 1.039 1.126 1.082 1.084
Lung Bladder Non-Hodgkin 
lymphoma
Hodgkin lym-
phoma
Multiple mye-
loma
Leukaemia
Age Male Female Male Female Male Female Male Female Male Female Male Female
0–4 0.711 0.849 0.107 0.141 0.824 0.823 0.476 0.000 1.000 1.000 0.356 0.354
5–9 0.711 0.849 0.107 0.141 0.716 0.502 0.304 0.972 1.000 1.000 0.280 0.224
10–14 0.711 0.849 0.107 0.141 0.791 0.664 0.226 0.493 1.000 1.000 0.483 0.525
15–19 0.711 0.849 0.107 0.141 0.850 0.859 0.159 0.191 1.000 1.000 0.703 0.684
20–24 0.711 0.849 0.107 0.141 0.953 0.767 0.303 0.204 1.000 1.000 0.865 0.815
25–29 0.711 0.849 0.107 0.159 1.261 0.673 0.280 0.161 0.431 0.318 0.883 0.936
30–34 0.926 0.849 0.182 0.393 1.381 0.677 0.507 0.259 0.670 0.619 0.814 0.796
35–39 0.939 0.849 0.157 0.533 1.320 0.565 0.492 0.422 0.485 0.540 0.866 0.872
40–44 0.922 0.890 0.344 0.459 1.107 0.521 0.794 0.346 0.591 0.622 0.702 0.801
45–49 0.909 0.891 0.443 0.452 0.872 0.526 1.145 0.744 0.556 0.525 0.770 0.882
50–54 0.920 0.891 0.459 0.405 0.715 0.576 1.262 1.084 0.700 0.725 0.780 0.830
55–59 0.932 0.918 0.550 0.522 0.713 0.630 1.401 1.683 0.684 0.669 0.811 0.829
60–64 0.954 0.937 0.756 0.637 0.809 0.760 2.194 2.317 0.800 0.785 0.899 0.880
65–69 0.986 0.979 0.751 0.764 0.860 0.877 2.581 3.020 0.898 0.762 0.991 0.959
70–74 1.039 1.038 1.069 0.878 1.003 1.058 3.753 3.912 1.139 0.942 1.192 1.068
75–79 1.090 1.038 1.305 1.199 1.251 1.428 4.263 4.686 1.231 1.196 1.404 1.185
80–84 1.169 1.038 1.740 1.520 1.531 1.654 4.979 4.303 1.535 1.451 1.501 1.337
85+ 1.219 1.038 2.453 1.956 1.863 2.105 5.372 6.393 1.828 1.743 1.563 1.535
Melanoma Miscellaneous Breast Cervix Uterus Ovary Pros-
tate
Age Male Female Male Female Female Female Female Female Male
0–4 1.000 3.573 0.514 0.430 0.874 0.574 0.322 0.247 0.548
5–9 1.000 1.000 0.444 0.405 0.874 0.574 0.322 0.247 0.548
10–14 0.324 0.706 0.395 0.299 0.874 0.574 0.322 0.247 0.548
15–19 0.959 0.937 0.377 0.222 0.874 0.574 0.322 0.202 0.548
20–24 0.670 0.531 0.279 0.147 0.874 0.425 0.322 0.241 0.548
25–29 0.764 0.455 0.229 0.154 0.679 0.329 0.553 0.173 0.548
30–34 0.564 0.493 0.261 0.207 0.733 0.406 0.382 0.236 0.548
35–39 0.902 0.542 0.375 0.270 0.651 0.457 0.353 0.336 0.548BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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The specification of relative interval survival (RISα,t,τ) for
age α, calendar year t across the interval (τ - 1) since diag-
nosis in years, separately for each cancer site, was of the
form:
RISα,t,τ = 1 - (1 - RIS1) Aα Tt Yτ   (1)
where RIS1 is the relative interval survival after 1 year for
all ages, averaged across the calendar years 1973 to 1997,
Aα is the ratio of the relative probability of death after 1
year at age α to the relative probability of death after 1
year for all ages averaged across the calendar years 1973 to
1997 ,  Tt is the ratio of the rel-
ative probability of death after 1 year for all ages in calen-
dar year t to the relative probability of death after 1 year
for all ages from 1973 to 1997   and Yτ is
the ratio of the relative probability of death after t years for
all ages to the relative probability of death after 1 year for
all ages from 1973 to 1997  .
To estimate survival for developing regions where little or
no data is available, we replaced Tt for the "equivalent"
calendar year survival term Tr in the equation (1) for each
region. Tr is the ratio of the relative probability of death af-
ter 1 year for all ages in the relevant region to the relative
probability of death after 1 year for all ages in the SEER da-
ta, averaged across the calendar years 1973 to 1997. In this
way, we obtain a new calendar year survival term for the
model.
Equivalent period survival terms were estimated for each
region by examining the relationship between period sur-
vival terms and gross domestic product per capita (meas-
ured in international dollars adjusted for purchasing
power parity) using the following data: 1) SEER survival
data for the USA for the years 1973 to 1997 [11,29]; 2)
Connecticut survival data for the years 1950 and 1958
[30]; 3) survival data for the late 1980s from cancer regis-
tries in 5 developing countries [31]; 4) survival data for
European countries [32]; 5) specific recent national esti-
mates of cancer survival as published [24,33]. Survivor-
ship functions were estimated to derive regional relative
survival from registry data by fitting a Weibull distribution
function. To allow for a proportion who are cured and
never die from the cancer, we modify the Weibull model
as follows:
S(t) = k + (1 - k) exp (-(λ t)γ)   (2)
where k is the proportion who never die from the cancer,
λ is the location parameter (1/λ is the time at which 50%
of those will die have died) and γ is the shape parameter.
The mean survival time for those who die ( ) is given by
where Γ denotes the gamma distribution. The analysis of
survival data in developed regions suggested that the 10-
year relative survival can be used as an estimate of the pro-
portion who never die from the cancer. This is particularly
useful when relative survival point estimates fluctuate sig-
nificantly and the plausible exact solutions did not ob-
tained as in some developing regions. To assess the
goodness-of-fit of the survival curve, we compared fitted
5-year survival with the observed survival and ensured the
good fits in all cases.
There are substantial variations in relative interval survival
(all ages) among countries; these variations are even larg-
er, and fluctuate substantially with age, when the age-sex
specific survival estimates are examined. There is also a
possibility of correlation among the observations within a
same region. Thus we employed both liner and non-linear
feasible generalised least squares (FGLS) by maximum
likelihood estimation to accommodate with hetero-
40–44 0.857 0.769 0.527 0.400 0.569 0.508 0.458 0.433 0.548
45–49 0.871 0.710 0.709 0.498 0.564 0.739 0.411 0.496 0.548
50–54 0.815 1.073 0.850 0.620 0.790 0.994 0.473 0.614 0.548
55–59 1.110 0.769 0.957 0.741 0.954 1.025 0.610 0.808 0.548
60–64 1.087 1.297 1.072 0.852 0.933 1.218 0.701 0.955 0.551
65–69 1.093 1.150 1.226 0.954 1.067 1.366 0.901 1.089 0.508
70–74 0.988 1.507 1.375 1.076 1.092 1.740 1.219 1.369 0.508
75–79 1.425 2.241 1.523 1.219 1.215 2.259 1.629 1.650 1.083
80–84 1.620 1.909 1.714 1.372 1.513 2.729 2.570 1.650 1.876
85+ 2.008 2.738 1.914 1.555 2.438 3.358 3.705 1.650 1.876
Table 3: Estimated age parameters (Aα) by cancer site, age and sex (Continued)
A
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Table 4: Estimated time since diagnosis (cohort) parameters (Yτ) by cancer site, year from diagnosis and sex
Oral Oesophagus Stomach Colon and rec-
tum
Liver Pancreas
Year Male Female Male Female Male Female Male Female Male Female Male Female
1 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2 0.877 0.855 0.752 0.753 0.640 0.564 0.609 0.572 0.591 0.542 0.721 0.720
3 0.542 0.472 0.462 0.483 0.387 0.349 0.443 0.388 0.368 0.352 0.434 0.430
4 0.377 0.329 0.313 0.251 0.251 0.186 0.345 0.267 0.265 0.219 0.257 0.226
5 0.300 0.268 0.214 0.216 0.173 0.117 0.240 0.189 0.268 0.174 0.156 0.170
6 0.235 0.282 0.175 0.181 0.109 0.099 0.185 0.134 0.116 0.104 0.150 0.108
7 0.241 0.268 0.173 0.109 0.087 0.065 0.144 0.114 0.118 0.083 0.116 0.092
8 0.217 0.224 0.145 0.168 0.063 0.084 0.094 0.085 0.073 0.093 0.100 0.104
9 0.211 0.241 0.095 0.168 0.035 0.068 0.079 0.068 0.041 0.075 0.062 0.078
10 0.236 0.213 0.084 0.138 0.048 0.046 0.068 0.059 0.000 0.049 0.085 0.051
11 0.219 0.197 0.057 0.145 0.016 0.041 0.024 0.033 0.000 0.045 0.047 0.048
12 0.217 0.180 0.030 0.142 0.000 0.031 0.000 0.014 0.000 0.034 0.029 0.036
13 0.214 0.164 0.004 0.139 0.000 0.021 0.000 0.000 0.000 0.022 0.010 0.023
14 0.211 0.147 0.000 0.137 0.000 0.010 0.000 0.000 0.000 0.010 0.000 0.010
15 0.208 0.131 0.000 0.134 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Lung Bladder Non-Hodgkin 
lymphoma
Hodgkin lym-
phoma
Multiple mye-
loma
Leukaemia
Year Male Female Male Female Male Female Male Female Male Female Male Female
1 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2 0.683 0.693 0.621 0.478 0.442 0.480 0.589 0.654 0.725 0.755 0.466 0.438
3 0.402 0.384 0.391 0.267 0.277 0.289 0.411 0.417 0.792 0.711 0.334 0.280
4 0.254 0.235 0.313 0.191 0.235 0.241 0.384 0.290 0.728 0.692 0.282 0.259
5 0.181 0.186 0.277 0.141 0.220 0.233 0.304 0.224 0.764 0.732 0.251 0.236
6 0.145 0.144 0.251 0.141 0.195 0.233 0.301 0.290 0.689 0.740 0.225 0.206
7 0.123 0.134 0.249 0.131 0.188 0.222 0.307 0.263 0.643 0.727 0.225 0.189
8 0.120 0.117 0.231 0.108 0.166 0.217 0.252 0.219 0.601 0.579 0.215 0.172
9 0.113 0.116 0.252 0.139 0.163 0.183 0.242 0.191 0.596 0.570 0.194 0.165
10 0.113 0.114 0.257 0.165 0.145 0.171 0.198 0.188 0.510 0.453 0.168 0.153
11 0.101 0.102 0.253 0.154 0.137 0.177 0.179 0.124 0.537 0.466 0.162 0.139
12 0.093 0.094 0.255 0.160 0.128 0.170 0.161 0.102 0.519 0.430 0.147 0.126
13 0.085 0.087 0.256 0.165 0.119 0.164 0.144 0.082 0.501 0.397 0.133 0.113
14 0.078 0.079 0.258 0.171 0.112 0.157 0.128 0.064 0.485 0.367 0.118 0.100
15 0.070 0.071 0.260 0.177 0.104 0.152 0.114 0.046 0.471 0.338 0.104 0.088
Melanoma Miscellaneous Breast Cervix Uterus Ovary Pros-
tate
Year Male Female Male Female Female Female Female Female Male
1 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2 0.967 0.972 0.423 0.361 1.205 0.869 0.656 0.726 1.108
3 0.801 0.962 0.215 0.194 1.297 0.507 0.418 0.461 1.142
4 0.622 0.741 0.152 0.127 1.154 0.337 0.233 0.315 1.065
5 0.459 0.514 0.109 0.091 1.051 0.232 0.141 0.232 1.051
6 0.392 0.531 0.097 0.079 0.926 0.196 0.118 0.169 1.038BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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scedasticity and correlation among the observations, and
chose the best fit model for each site [34]. We did not in-
clude region fixed-effects since the data are not available
for all sub regions.
Model estimation of cancer death distribution
For the estimation of the number of deaths and cancer
death distribution by site, we needed to estimate the
number of individuals who survived up to 2000 by age
and time of survival as well as their corresponding proba-
bility of death during this year. The number of surviving
individuals at age α in 2000 was calculated by multiplying
incidence at age α in year (2000 - τ) by the observed inter-
val survival for τ years since diagnosis for individuals aged
α in 2000 (OISα,τ), and summing over τ. To estimate OI-
Sα,τ, we first calculated the relative cumulative survival
(RCSα,τ) for every single age and year of survival for 2000,
by multiplying RISα,τ over the years of survival. In a stand-
ard life table format, OISα,τ is written of the from:
where lx is the number of individuals surviving at exact age
x in the life table, hx = ln (lx+1/lx), α is age and τ is time
since diagnosis.
The number of individuals Sα,τ who had survived up to
2000 was by multiplying incidence and observed interval
survival for the corresponding year of age and survival
time:
Sα,τ = Iα-τ,2000-τOISα,τ   (5)
where Iα,t is the incidence at age α in calendar year t. For
example, the number of individuals who were 7 years of
age (α = 7) in 2000, and who had survived cancer for 4
years (τ = 4) in 2000 was calculated by multiplying the in-
cidence of cancer for the cohort of individuals who were 3
years of age (α - τ = 3) in 1996 ( = 2000 - τ) (year of diag-
nosis) by the OISα,τ calculated for a 7 year old person who
had survived 4 years since cancer diagnosis.
The probability of dying in 2000 due to cancer hazard, for
each single age and year of survival, was calculated as fol-
lows:
Pα,τ = [1 - exp (-(-ln (RIS α,τ) + hα))] [-ln (RISα,τ)/(-ln (RIS
α,τ) + hα)]   (6)
For each site, the number of deaths in 2000, among those
individuals aged α years and who had survived cancer for
τ years, was estimated by multiplied the number of survi-
vors Sα,τ by the relevant probability of dying in 2000 due
to cancer hazard Pα,τ. The total cancer deaths of the same
site in 2000 at age α years is then estimated by summing
over all survival times τ:
Based on these region-specific adjusted incidence esti-
mates and survival levels, cancer deaths were calculated by
equations (3)-(6) for each region by age group and sex to
estimate the distribution, but not the magnitude, of can-
cer by site, sex, and age group.
Validation of the model
We tested the validity and performance of the proposed
survival model in three different ways. Firstly, we com-
pared our estimated RISα,t,τ for τ = 1 to 10 years individu-
als diagnosed with cancer in 1986 with the SEER RISα,t,τ
for τ = 1 to 10 years for the same cohort of individuals.
Secondly, we compared the model estimates of cancer
mortality distribution with the observed distributions in
the regions with good vital records (AmrB, EurA, EurB,
EurC and WprA sub regions). AmrA sub region was ex-
cluded for the validation purpose since it includes the
United States. Finally we compared the cancer death dis-
tribution of our model with the Globocan 2000 estimates
for the regions where no vital records are available (AfrD,
7 0.280 0.339 0.082 0.067 0.879 0.162 0.070 0.110 1.113
8 0.239 0.329 0.070 0.056 0.744 0.146 0.066 0.113 1.099
9 0.220 0.248 0.069 0.052 0.756 0.095 0.048 0.089 1.022
10 0.085 0.217 0.066 0.050 0.705 0.119 0.038 0.061 1.013
11 0.101 0.117 0.054 0.039 0.633 0.078 0.014 0.038 1.015
12 0.026 0.045 0.047 0.032 0.576 0.056 0.000 0.014 1.001
13 0.000 0.000 0.039 0.025 0.520 0.034 0.000 0.000 0.987
14 0.000 0.000 0.032 0.017 0.464 0.012 0.000 0.000 0.973
15 0.000 0.000 0.024 0.010 0.407 0.000 0.000 0.000 0.959
Table 4: Estimated time since diagnosis (cohort) parameters (Yτ) by cancer site, year from diagnosis and sex (Continued)
OIS RCS l l RCS hx
x
ατ ατ α α τ ατ
ατ
α
,, , / exp ln = () =− − () +
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
 +− +
=− +
∑ 11
1
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
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




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
 () 4
DS P αα τ
τ
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Table 5: Estimated period parameters (Tt) for 1981–1995 by cancer site, calendar year, and sex
Oral Oesophagus Stomach Colon and rec-
tum
Liver Pancreas
Year Male Female Male Female Male Female Male Female Male Female Male Female
1981 0.991 1.035 1.121 1.180 1.060 1.003 0.983 1.013 1.092 1.092 1.004 1.022
1982 1.019 1.048 1.054 0.971 0.949 1.066 0.986 1.017 1.031 1.036 0.998 1.014
1983 1.065 1.095 1.046 1.046 0.939 0.992 0.989 1.026 1.019 1.033 0.997 0.980
1984 0.925 1.090 0.959 0.944 1.051 0.967 0.998 0.938 0.991 1.053 1.039 0.989
1985 0.895 1.053 0.975 0.957 0.993 0.994 0.904 0.949 0.974 1.000 1.018 1.022
1986 1.070 0.910 0.997 0.995 1.007 0.900 0.850 0.893 1.015 1.028 0.988 1.000
1987 0.994 0.979 0.996 0.954 1.002 0.976 0.883 0.904 0.952 0.966 0.988 0.987
1988 0.954 0.887 0.998 0.925 0.940 0.918 0.914 0.917 1.009 1.030 0.976 1.008
1989 1.104 0.984 0.933 0.943 0.919 0.980 0.870 0.876 0.944 1.029 0.984 0.967
1990 1.000 0.896 0.886 1.049 0.937 0.956 0.824 0.867 0.959 0.985 0.972 0.986
1991 0.991 0.959 0.880 0.893 0.998 0.932 0.810 0.824 0.969 0.944 0.962 0.974
1992 1.070 0.992 0.889 0.902 0.952 0.903 0.832 0.871 1.011 0.959 0.993 0.949
1993 0.998 0.865 0.904 1.017 0.966 0.944 0.888 0.894 0.972 0.982 0.994 0.985
1994 0.842 0.965 0.936 0.938 0.935 0.966 0.833 0.875 0.933 0.914 0.964 0.983
1995 0.899 0.942 0.887 0.927 0.900 0.981 0.896 0.971 0.942 0.943 0.995 0.987
Lung Bladder Non-Hodgkin 
lymphoma
Hodgkin lym-
phoma
Multiple mye-
loma
Leukaemia
Year Male Female Male Female Male Female Male Female Male Female Male Female
1981 1.020 1.017 0.916 1.052 0.882 0.960 0.994 1.675 0.985 1.107 1.004 0.916
1982 0.994 1.000 1.179 0.775 1.033 1.069 1.240 0.888 1.008 0.837 1.042 1.043
1983 0.988 0.996 0.998 1.005 0.788 0.946 0.840 1.009 0.809 0.975 1.033 1.030
1984 0.994 1.009 1.090 0.762 0.883 0.999 0.756 0.775 1.066 1.018 0.981 0.985
1985 0.997 0.972 0.972 1.039 0.949 1.021 0.834 0.947 0.914 0.989 0.962 0.963
1986 0.976 0.986 0.925 0.883 1.010 1.102 0.994 0.579 1.015 0.911 0.982 0.936
1987 0.977 1.015 0.885 0.995 1.016 0.898 0.867 0.880 0.795 0.876 0.959 1.023
1988 0.980 0.995 0.851 0.859 1.043 0.967 0.854 0.978 0.866 0.930 0.905 0.937
1989 0.982 0.981 0.746 0.908 1.064 0.997 1.036 0.747 0.969 0.966 0.977 0.946
1990 0.982 0.985 0.869 1.040 1.125 0.959 0.863 1.021 0.996 0.938 0.918 0.930
1991 0.968 0.971 0.918 0.907 1.115 0.991 0.634 0.811 0.782 0.880 0.930 0.959
1992 0.964 0.986 0.894 0.942 1.059 1.000 0.831 0.579 0.946 1.176 0.920 0.925
1993 0.979 0.977 0.844 0.897 1.069 0.965 0.998 0.583 1.036 0.834 0.927 0.972
1994 0.975 0.990 0.844 0.935 1.091 0.987 0.590 0.787 0.892 0.965 0.927 1.018
1995 0.968 0.990 0.815 0.878 1.116 1.007 0.719 0.655 0.895 0.936 0.952 1.026
Melanoma Miscellaneous Breast Cervix Uterus Ovary Pros-
tate
Year Male Female Male Female Female Female Female Female Male
1981 1.230 1.467 0.928 1.089 1.182 1.091 1.229 1.076 1.589
1982 1.332 0.765 0.921 1.060 1.131 1.020 1.160 1.036 1.556
1983 0.830 0.689 0.894 1.044 1.174 0.862 1.104 1.039 1.454
1984 1.124 0.567 0.902 0.996 1.095 0.921 1.160 0.931 1.411
1985 1.014 0.979 0.855 0.994 1.056 1.041 0.932 0.972 1.301
1986 0.838 0.830 0.862 0.966 0.949 1.132 0.953 1.084 1.358BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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AfrE, SearB and SearD sub regions) to assess whether our
model estimates are comparable to the estimates extrapo-
lated from the actual observed data from the registries. In
all cases, non-parametric tests for trends and Pearson's
correlation were performed to examine whether the mod-
els estimates and observed data are consistent with each
other. All statistical analysis was performed by STATA 7.0
(STATA corporation, College Station, TX).
Results
Parameter estimates
Relative interval survival (RIS) was directly obtained from
the SEER database for every age group, sex, and cancer site
The probability of death in the first year (1 - RIS1), which
is most crucial for the survival of most cancer patients, is
shown in Table 2. The probability of death varied signifi-
cantly from less than 5% in cancers of melanoma, breast,
uterus, and prostate to over 80% in pancreas and liver can-
cers.
Relative interval survival (RIS) was further indexed to the
three parameters in the multiplicative cancer survival
model by dividing each of the time-specific probability of
death (1 - RIS) by the probability of death at 1-year inter-
val (1 - RIS1). Tables 3,4,5 represent the indexed estimates
of three parameters by site for every 5-year age group from
0 up to 85+ years of age, and for calendar year from 1981
to 1995, and for time since cancer diagnosis from 1- up to
15-year survival, respectively. While there is considerable
variation in the cohort parameters which reflect the prog-
nosis among patients since the time of diagnosis, both age
and period parameters are generally consistent across dif-
ferent types of cancer.
Based on the fitted data for each site and sex, and the esti-
mated GDP per capita in international dollars for each re-
gion in 2000, Tr factors were estimated for each site and
sex for each GBD 2000 region. The results are presented in
Table 6. An example is shown for breast cancer: knowing
that GDP per capita in AfrD was $1,158 in 2000, this cor-
responded to an indexed calendar year-specific Tt = 2.748.
This was then the value used in the age-period-cohort sur-
vival model for breast cancer in the AfrD sub region. A
similar process was applied to the other regions and for
other cancer sites.
The period parameters (Tr) for all the available survival
data and fitted values from regression analysis were plot-
ted against GDP per capita (international dollars) for each
site and sex as shown in Figures 1,2,3,4,5,6. The largest
variation in survival was observed among cancers of
breast, melanoma of the skin, and hematological malig-
nancies such as lymphoma and leukemia. For the cancers
of cervix and colon and rectum, both early detection and
availability of treatment determine the survival and the
variation among regions were moderate. On the other
hand, cancers with very poor prognosis such as liver, lung,
and pancreas cancers showed very small variations across
the regions regardless of the levels of national income.
Model performance and validation
In order to check the performance of the model, we graph-
ically compared our estimated RISα,t,τ for τ = 1 to 10 years
individuals diagnosed with cancer in 1986 with the SEER
RISα,t,τ for τ = 1 to 10 years for the same cohort of individ-
uals. We show the results obtained for males and females
55–59 years old, and for every cancer site in Figures 7,8,9.
From these figures, we can observe that the model predicts
very well the relative interval survivals. For those cancer
sites with greater number of cases, such as colon, lung,
breast, corpus uteri, and prostate cancer, the model fits
very well. For those with smaller numbers such as cancers
of liver and pancreas, the estimated RIS  smoothes the
curves for the observed RIS, also showing a very good fit.
We also tested the validity of our model when applied to
other populations. We have chosen the age groups from
45 to 79 in which cancer mortality rate is relatively stable
and the probability of miscoding of cause of death is
small. Figures 10,11 shows the comparison between mod-
el estimates and vital registration data for six sub regions
in age group 65–69 (AmrB, EurA, EurB1, EurB2, EurC,
and WprA sub regions). The estimated coefficients and p-
values for the test of Pearson's correlation by using all data
1987 0.971 1.038 0.843 0.982 0.810 0.993 1.089 1.015 1.210
1988 0.784 0.633 0.871 0.977 0.810 1.002 1.056 0.926 0.976
1989 1.124 0.969 0.823 0.954 0.764 0.870 1.047 0.849 0.833
1990 0.925 0.945 0.784 0.941 0.779 0.941 1.001 0.833 0.651
1991 0.757 0.574 0.770 0.894 0.695 0.881 1.075 0.817 0.309
1992 0.838 1.197 0.806 0.897 0.667 1.002 0.955 0.738 0.278
1993 0.902 0.813 0.803 0.910 0.723 0.848 1.042 0.827 0.226
1994 0.610 1.163 0.777 0.891 0.649 0.985 1.115 0.836 0.299
1995 0.757 0.543 0.805 0.910 0.721 0.862 0.968 0.779 0.290
Table 5: Estimated period parameters (Tt) for 1981–1995 by cancer site, calendar year, and sex (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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Figure 1
Observed and fitted period factor by region (Tr) versus GDP per capita (1)
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Table 6: Estimated regional period parameters (Tr) for 2000 by cancer site and sex
Oral Oesophagus Stomach Colon and rec-
tum
Liver Pancreas
Region Male Female Male Female Male Female Male Female Male Female Male Female
AfrD 2.132 1.493 1.072 1.119 1.070 1.198 1.892 1.794 1.050 1.102 1.003 1.049
AfrE 2.111 1.486 1.065 1.117 1.069 1.195 1.880 1.784 1.050 1.101 1.003 1.048
AmrA 0.887 0.873 0.975 0.973 0.965 0.930 0.845 0.859 0.985 1.000 1.002 0.994
AmrB 1.747 1.357 1.017 1.087 1.047 1.140 1.663 1.590 1.046 1.080 1.003 1.037
AmrD 1.984 1.443 1.040 1.107 1.061 1.177 1.809 1.720 1.049 1.094 1.003 1.044
EmrB 1.774 1.368 1.019 1.089 1.049 1.144 1.681 1.606 1.046 1.082 1.003 1.038
EmrD 2.005 1.451 1.043 1.109 1.063 1.180 1.821 1.731 1.049 1.095 1.003 1.045
EurA 1.122 1.059 0.985 1.017 0.997 1.011 1.160 1.141 1.017 1.030 1.002 1.010
EurB1 1.797 1.376 1.021 1.091 1.050 1.148 1.695 1.618 1.047 1.083 1.003 1.038
EurB2 2.069 1.472 1.054 1.114 1.066 1.189 1.857 1.763 1.050 1.099 1.003 1.047
EurC 1.868 1.402 1.027 1.097 1.055 1.159 1.739 1.658 1.048 1.087 1.003 1.041
SearB 1.933 1.426 1.033 1.103 1.058 1.169 1.778 1.693 1.049 1.091 1.003 1.043
SearD 2.127 1.491 1.071 1.118 1.070 1.197 1.890 1.792 1.050 1.102 1.003 1.048
WprA 0.979 0.958 0.979 0.993 0.980 0.967 0.989 0.987 1.001 1.014 1.002 1.001
WprB1 1.990 1.445 1.041 1.108 1.062 1.178 1.812 1.723 1.049 1.095 1.003 1.044
WprB2 2.095 1.481 1.061 1.116 1.068 1.193 1.872 1.776 1.050 1.100 1.003 1.048
WprB3 1.967 1.437 1.038 1.106 1.060 1.174 1.799 1.711 1.049 1.093 1.003 1.044
Lung Bladder Non-Hodgkin 
lymphoma
Hodgkin lym-
phoma
Multiple mye-
loma
Leukaemia
Region Male Female Male Female Male Female Male Female Male Female Male Female
AfrD 1.141 1.212 3.526 2.844 1.466 1.581 2.176 2.419 1.081 1.213 1.539 1.493
AfrE 1.139 1.210 3.492 2.819 1.459 1.574 2.160 2.399 1.080 1.209 1.532 1.486
AmrA 0.984 0.995 0.493 0.653 0.891 0.913 0.676 0.557 0.945 0.907 0.880 0.875
AmrB 1.107 1.165 2.864 2.365 1.340 1.435 1.849 2.013 1.052 1.146 1.395 1.358
AmrD 1.129 1.195 3.284 2.669 1.420 1.528 2.057 2.271 1.070 1.188 1.487 1.444
EmrB 1.110 1.169 2.915 2.402 1.350 1.447 1.874 2.044 1.054 1.151 1.406 1.368
EmrD 1.131 1.198 3.320 2.695 1.427 1.536 2.075 2.293 1.072 1.192 1.494 1.451
EurA 1.031 1.061 1.405 1.312 1.064 1.114 1.127 1.117 0.986 0.999 1.078 1.061
EurB1 1.112 1.172 2.956 2.432 1.358 1.456 1.894 2.069 1.056 1.155 1.415 1.377
EurB2 1.136 1.205 3.424 2.771 1.447 1.559 2.126 2.357 1.077 1.203 1.517 1.472
EurC 1.118 1.181 3.083 2.524 1.382 1.484 1.957 2.148 1.061 1.168 1.443 1.403
SearB 1.124 1.189 3.197 2.606 1.403 1.509 2.014 2.217 1.067 1.180 1.468 1.426
SearD 1.141 1.212 3.519 2.839 1.464 1.580 2.173 2.415 1.081 1.212 1.538 1.492
WprA 1.006 1.025 0.908 0.953 0.970 1.004 0.881 0.812 0.964 0.949 0.970 0.959
WprB1 1.129 1.196 3.294 2.676 1.422 1.530 2.062 2.277 1.071 1.189 1.489 1.446
WprB2 1.138 1.208 3.468 2.802 1.455 1.569 2.148 2.384 1.079 1.207 1.527 1.481
WprB3 1.127 1.193 3.255 2.648 1.414 1.522 2.043 2.253 1.069 1.186 1.480 1.438
Melanoma Miscellaneous Breast Cervix Uterus Ovary Pros-
tate
GDP 
Per 
capita
Region Male Female Male Female Female Female Female Female Male
AfrD 3.811 6.596 1.720 1.741 2.748 1.647 1.896 1.261 5.559 1,158
AfrE 3.775 6.174 1.709 1.731 2.725 1.638 1.885 1.247 5.505 1,465
AmrA 0.452 0.819 0.718 0.849 0.657 0.845 0.881 1.064 0.647 28,910
AmrB 3.093 3.311 1.501 1.546 2.292 1.472 1.674 1.149 4.487 7,217
AmrD 3.550 4.680 1.640 1.670 2.582 1.583 1.815 1.196 5.168 3,367
EmrB 3.149 3.431 1.518 1.561 2.327 1.485 1.692 1.153 4.570 6,749
EmrD 3.589 4.864 1.652 1.680 2.606 1.592 1.827 1.202 5.226 3,040
EurA 1.481 1.431 1.019 1.117 1.286 1.086 1.186 1.085 2.125 20,562BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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points in age groups from 45 to 79 were also presented.
When compared with site-specific mortality distribution
of the Globocan 2000 based on regional cancer registries
for AFRO and SEARO regions, the model estimate also
yielded consistent mortality distribution pattern (Figure
12). In all cases, the correlation coefficients were in the
range of 0.91 to 0.98, suggesting that model estimates for
these regions are quite consistent with the observed cancer
mortality distribution.
Probability of 5-year survival and mean duration by site
The proposed model also yields RIS for various years and
the mean duration of cancer by site, both of which are im-
portant inputs for the future estimation of cancer morbid-
ity burden in terms of years lived with disability (YLDs).
As an illustration of the further use of our model, Figures
13 and 14 show, respectively, the conventional 5-year sur-
vival and average duration for the female cancer patients
aged 45–54 in four different sub regions (AfrE, AmrA,
SearD and WprB3). Depending on the site, the chance of
5-year survival and average duration varied considerably
across the resigns, which are consistent with the estimated
survival pattern above.
Discussion
As a part of the Global Burden of Disease 2000 (GBD
2000) study, we have developed a multiplicative model of
relative interval survival for cancer by site based on the
best available evidence from published population-based
survival data from both developed and developing coun-
tries. Because of the sparseness of survival data for the de-
veloping regions of the world, we decided to use all the
available data, including the most valuable cancer registry
data compiled by the International Agency for Research
on Cancer (IARC), national cancer registries, and lengthy
time series data from the United States, to establish trends
in survival with gross domestic product (GDP) per capita
and then to use latest estimates of GDP per capita for de-
veloping regions, in order to estimate survival by site.
This approach takes into account, through increases in av-
erage GDP per capita for regions, the likely improvements
in survival over the periods since those for which develop-
ing country survival data are available. Since our survival
model adjusted for age and differences in competing mor-
tality in each population by employing relative interval
survival, the remaining variations in survival are likely to
be due to differences in diagnosis and availability of ap-
propriate treatment options. For instance, the large varia-
tion in survival was observed among cancers of bladder,
breast, melanoma of the skin, and hematological malig-
nancies such as lymphoma and leukemia for which effec-
tive therapy is established in developed regions. For the
cancers of cervix and colon and rectum, both early detec-
tion and availability of treatment determine the survival
and the variation among regions were moderate. On the
other hand, cancers with very poor prognosis showed very
small variations across the regions. The survival pattern
across the regions are consistent with previous analysis
based on the IARC cancer registry data [35].
The proposed model takes into account time in its three
dimensions: age, calendar year (period) and time since
cancer (cohort) and, due to the availability of data, the
model outcome was compared the to the data reported by
the US vital statistics and other regions of the world. This
has given us the opportunity to evaluate our model and
the data available.
However, perhaps the main advantage of this approach to
estimating regional survival distributions by cancer site
for developing regions is that the model correctly esti-
mates survival and smoothes it and ensures that regional
survival estimates are consistent with trends in survival
across all regions, where the numbers for some cancer
sites are small and highly fluctuate, and are inconsistent
with other regions. For example, as can be seen in Figure
1a, cancer registry survival estimates for some sites in
some developing countries are better than recent experi-
ence in the United States, or significantly below the trend
line with GDP per capita, suggesting that survival may
have been overestimated due to small numbers or incom-
plete case follow-up. In these cases, the survival model
provides survival estimates more consistent with the com-
EurB1 3.194 3.535 1.532 1.573 2.355 1.496 1.705 1.157 4.637 6,371
EurB2 3.702 5.541 1.687 1.711 2.678 1.620 1.862 1.225 5.395 2,085
EurC 3.332 3.897 1.574 1.611 2.443 1.530 1.748 1.169 4.843 5,206
SearB 3.455 4.297 1.611 1.644 2.521 1.560 1.786 1.183 5.027 4,168
SearD 3.804 6.506 1.718 1.739 2.744 1.645 1.894 1.258 5.549 1,218
WprA 0.922 1.072 0.855 0.971 0.943 0.954 1.020 1.073 1.319 25,115
WprB1 3.561 4.728 1.644 1.673 2.589 1.585 1.819 1.198 5.184 3,277
WprB2 3.749 5.920 1.701 1.724 2.708 1.631 1.877 1.238 5.466 1,688
WprB3 3.519 4.545 1.631 1.661 2.562 1.575 1.806 1.191 5.122 3,631
Table 6: Estimated regional period parameters (Tr) for 2000 by cancer site and sex (Continued)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/36
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Figure 2
Observed and fitted period factor by region (Tr) versus GDP per capita (2)
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Figure 3
Observed and fitted period factor by region (Tr) versus GDP per capita (3)
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Figure 4
Observed and fitted period factor by region (Tr) versus GDP per capita (4)
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Figure 5
Observed and fitted period factor by region (Tr) versus GDP per capita (5)
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Figure 6
Observed and fitted period factor by region (Tr) versus GDP per capita (6)
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Figure 7
Comparison between predicted and observed relative interval survival for 55–59 year olds for 15 cancer sites, 
by sex, 1986 (1)
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Figure 8
Comparison between predicted and observed relative interval survival for 55–59 year olds for 15 cancer sites, 
by sex, 1986 (2)
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Figure 9
Comparison between predicted and observed relative interval survival for 55–59 year olds for 15 cancer sites, 
by sex, 1986 (3)
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Figure 10
Mortality distribution by site: comparison between model estimates and vital registration data in three sub 
regions (AmrB, EurA, and EurB1) Cancer site: 1 = mouth and pharynx, 2 = oesophagus, 3 = stomach, 4 = colon and rec-
tum, 5 = liver, 6 = pancreas, 7 = trachea, bronchus and lung, 8 = melanoma of the skin, 9 = breast, 10 = cervix uteri, 11 = cor-
pus uteri, 12 = ovary, 13 = prostate, 14 = bladder, 15 = lymphomas and multiple myeloma, 16 = leukaemia. r = Pearson's 
correlation coefficient when analysed with all data in age groups 45–79.
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Figure 11
Mortality distribution by site: comparison between model estimates and vital registration data in three sub 
regions (EurB2, EurC, and WprA) Cancer site: 1 = mouth and pharynx, 2 = oesophagus, 3 = stomach, 4 = colon and rec-
tum, 5 = liver, 6 = pancreas, 7 = trachea, bronchus and lung, 8 = melanoma of the skin, 9 = breast, 10 = cervix uteri, 11 = cor-
pus uteri, 12 = ovary, 13 = prostate, 14 = bladder, 15 = lymphomas and multiple myeloma, 16 = leukaemia. r = Pearson's 
correlation coefficient when analysed with all data in age groups 45–79.
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plete body of evidence. The second advantage of the pro-
posed approach is that the model is flexible enough to
yield the survival estimates of various age, years and peri-
od as well as mean duration of time of cancer by site. In
addition to mortality and incidence estimates[36], such
information is required to estimate the cancer burden in
terms of disability-adjusted life years (DALYs) in the fu-
ture analysis for the GBD 2000[1].
The main limitations for applying this model were the rel-
ative lack of region-specific survival data and very few, and
probably not always representative, regional cancer inci-
dence data for some developing regions. We assumed that
cancer incidence reported by a few countries of one region
or sub region would represent the incidence of the whole
area, which may not always be the case.
It is suggested that model-based estimates of cancer mor-
tality in the previous GBD 1990 study did not reflect the
actual profile of cancer recorded at the regional registries,
in particular of site-specific cancer mortality distribution
[3,5,37]. Although population-based estimates from can-
cer registry data should be incorporated, they may not to
be representative of the whole countries they should rep-
resent. Such estimates are sometimes restricted to certain
geographic areas and also related to the extent of health
care and surveillance system. Furthermore, several devel-
Figure 12
Mortality distribution by site: comparison between model estimates and previous estimates based on cancer 
registration data in AFRO and SEARO regions Cancer site: 1 = mouth and pharynx, 2 = oesophagus, 3 = stomach, 4 = 
colon and rectum, 5 = liver, 6 = pancreas, 7 = trachea, bronchus and lung, 8 = melanoma of the skin, 9 = breast, 10 = cervix 
uteri, 11 = corpus uteri, 12 = ovary, 13 = prostate, 14 = bladder, 15 = lymphomas and multiple myeloma, 16 = leukaemia. r = 
Pearson's correlation coefficient when analysed with all data in age groups 45–79.
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oping regions of the world were not included in these es-
timates, and the need to produce model-based estimates
would persist.
Contrary to the previous GBD 1990 model, the present
survival model specifically developed for the GBD 2000
incorporated all available survival information obtained
from registries and corrected for possible bias. The model
was used to estimate the distribution of death by site not
the actual magnitude of cancer mortality in regions where
no or little data on detailed cause of death is available. In
fact, the model estimates were quite comparable to the
mortality distribution estimated from vital registration
records. Furthermore, when for the regions where vital
records are not available, our model was consistent with
the Globocan 2000 estimates based on the regional regis-
tries [6].
Conclusions
The survival model presented offers a new approach to the
calculation of the number and distribution of deaths for
areas where mortality data are either scarce or unavailable.
It can also be applied in areas with good quality data, but
where there are small numbers of some site-specific can-
cers. The model is flexible enough to estimate some of the
parameters required to estimate the cancer burden. In our
future work, we will attempt to collect further information
on survival and incidence from more individual countries
in order to improve our estimates, with more precise in-
puts for the model.
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Figure 13
Five-years survival rate by site in four sub regions, females, age 45–54
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